Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Recommendation of “Buy” from Analysts

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has been given a consensus rating of “Buy” by the six brokerages that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $42.75.

Several research analysts recently commented on KLRA shares. Evercore started coverage on Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating for the company. Leerink Partners assumed coverage on shares of Kailera Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $30.00 target price for the company. TD Cowen started coverage on shares of Kailera Therapeutics in a research report on Tuesday. They set a “buy” rating and a $57.00 price target on the stock. Finally, Wall Street Zen raised shares of Kailera Therapeutics to a “hold” rating in a research note on Saturday, April 25th.

Insider Buying and Selling

In other news, Director Adam Koppel purchased 1,562,500 shares of the business’s stock in a transaction dated Monday, April 20th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the director directly owned 22,583,268 shares of the company’s stock, valued at approximately $361,332,288. This represents a 7.43% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Rtw Investments, Lp bought 500,000 shares of Kailera Therapeutics stock in a transaction on Monday, April 20th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the transaction, the insider directly owned 10,776,820 shares of the company’s stock, valued at approximately $172,429,120. This trade represents a 4.87% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders bought 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Stock Performance

Shares of Kailera Therapeutics stock traded up $0.01 on Tuesday, reaching $22.94. The company’s stock had a trading volume of 61,974 shares, compared to its average volume of 850,625. Kailera Therapeutics has a 52-week low of $20.86 and a 52-week high of $28.23.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.